FDA

Commonly Overlooked Areas of Savings for Hospitals (Part 2 of 2)

April 22, 2013

In our last posting, we began looking at the Huron Consulting Group’s recent report titled “Ten Overlooked Opportunities for Significant Performance Improvement and Cost Savings.” We covered the first five areas of the report, and now, we move into the final five. The report looks at potentially “untapped” savings that internal improvement teams should be […]

VN:F [1.9.7_1111]
Rating: 0 (from 0 votes)
0 comments Read the full article →

Da Vinci Robot Comes Under Scrutiny

April 10, 2013

Many of the organizations HCE has interviewed over the years have invested millions of dollars in the popular da Vinci surgical robot. When asked, these organizations almost always give the robot positive reviews and feel the investment was worthwhile. However, as The Associated Press reports, “The Food and Drug Administration is looking into an increase […]

VN:F [1.9.7_1111]
Rating: 0 (from 0 votes)
0 comments Read the full article →

Advocates say FDA guidelines far too lax

November 5, 2010

For those who don’t know how the agency works, the following may come as a surprise, but it’s indeed the way the FDA does business.  While most state and federal agencies rely on regulations, and in most cases get really nasty when those regs aren’t followed, the FDA issues “guidance.” We’re talking voluntary guidance, not […]

VN:R_U [1.9.7_1111]
Rating: +4 (from 4 votes)
0 comments Read the full article →

NPR blogger: CVS stores were favorites of meth-cooking “smurfers”

October 18, 2010
smurf

Maybe it’s just old age, but I remember when a smurf was just an obnoxious animated character without any redeeming value whatsoever. Apparently, those days are long gone. Those who run about buying OTC decongestants for use in cooking up methamphetamine are known as “smurfers.” And according to NPR blogger Scott Hensley, until recently they looooved […]

VN:F [1.9.7_1111]
Rating: +4 (from 4 votes)
0 comments Read the full article →

FDA Avandia rules may driven by politics

September 30, 2010
Pharmaceuticals

If the stats on its clinical risks are so negative, why is diabetes drug Avandia still on the U.S. market? Well, according to blogger John Mack, a pharma industry insider who keeps a close eye on these things, the answer may have more to do with politics than medicine. As things stand, European regulators have […]

VN:F [1.9.7_1111]
Rating: +1 (from 1 vote)
Read the full article →